Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press102210.17650/1726-9776-2008-4-4-11-16DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиThe role of sorafenib (Nexavar) in the treatment of inoperable locally advanced and disseminated renal cell cancerРоль сорафениба (Нексавар) в лечении неоперабельного местно-распространенного и диссеминированного почечно-клеточного ракаMatveyevB. P.МатвеевБ. П.
Russian Federation

Moscow

Москва

MatveyevV. B.МатвеевВ. Б.
Russian Federation

Moscow

Москва

VolkovaM. I.ВолковаМ. И.
Russian Federation

Moscow

Москва

State Enterprise N.N. Blokhin Russian Cancer Research Center of Russian Academy of Medical SciencesГУ РОНЦ им. Н.Н. Блохина РАМН301220084411161202202012022020https://oncourology.abvpress.ru/oncur/article/view/1022

Efficacy and safety issues of sorafenib (Nexavar) use in the treatment of patients with inoperable locally advanced and disseminated renal cell cancer are addressed. Several clinical studies of efficacy of treatment with sorafenib both in mono-regimen and combined with other drugs are discussed.

.

1. Аксель Е.М. Заболеваемость злокачественными новообразованиями мочевых и мужских половых органов в России в 2003 г. Онкоурология 2005;(1):6—9.Аксель Е.М. Заболеваемость злокачественными новообразованиями мочевых и мужских половых органов в России в 2003 г. Онкоурология 2005;(1):6—9.2. Yagoda A. Petrylak D., Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993;20:303.Yagoda A. Petrylak D., Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993;20:303.3. Papac R.J., Keohane M.F. Hormonal therapy for metastatic renal cell carcinoma combined androgent and prover followed by high dose tamoxifen. Eur J Cancer 1993;29A:997.Papac R.J., Keohane M.F. Hormonal therapy for metastatic renal cell carcinoma combined androgent and prover followed by high dose tamoxifen. Eur J Cancer 1993;29A:997.4. Savage P.D., Muss H.B. Renal cell cancer. Philadelphia, Lippincott Co; 1995. p. 373—87.Savage P.D., Muss H.B. Renal cell cancer. Philadelphia, Lippincott Co; 1995. p. 373—87.5. Negrier S., Escudier B., Dovillard J.Y. et al. Randomized study of interleukin-2 (IL-2) and interferon (IFN) with or without 5-FU (FUCY study) in metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 1997;16:1161.Negrier S., Escudier B., Dovillard J.Y. et al. Randomized study of interleukin-2 (IL-2) and interferon (IFN) with or without 5-FU (FUCY study) in metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 1997;16:1161.6. Motzer R.J., Bacik J., Schwartz L.H. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454—63.Motzer R.J., Bacik J., Schwartz L.H. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454—63.7. Mercer K.E., Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25—40.Mercer K.E., Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25—40.8. Lyons J.F., Wilhelm S., Hibner B., Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219—25.Lyons J.F., Wilhelm S., Hibner B., Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219—25.9. Wilhelm S.M., Carter C., Tang L. et al BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099—109.Wilhelm S.M., Carter C., Tang L. et al BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099—109.10. Levy A.P., Pauloski N., Braun D. et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc Am Assoc Cancer Res 2006;47:213—4.Levy A.P., Pauloski N., Braun D. et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc Am Assoc Cancer Res 2006;47:213—4.11. Chang Y.S., Adnane L., Henderson A. et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor necrosis in the human RCC xenograft model, 786-O. Clin Cancer Res 2005;11:9011.Chang Y.S., Adnane L., Henderson A. et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor necrosis in the human RCC xenograft model, 786-O. Clin Cancer Res 2005;11:9011.12. Clark J.W., Eder J.P., Ryan D. et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 439006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472—80.Clark J.W., Eder J.P., Ryan D. et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 439006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472—80.13. Awada A., Hendlisz A., Gil T. et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855—61.Awada A., Hendlisz A., Gil T. et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855—61.14. Moore M., Hirte H.W., Siu L. et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688—94.Moore M., Hirte H.W., Siu L. et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688—94.15. Strumberg D., Richly H., Hilger R.A. et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965—72.Strumberg D., Richly H., Hilger R.A. et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965—72.16. Wright J., Zerivitz K., Gravell A. Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1. Oncology (Williston Park) 2005;19:499—502.Wright J., Zerivitz K., Gravell A. Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1. Oncology (Williston Park) 2005;19:499—502.17. Ratain M.J., Eisen T., StadlerW.M. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505—12.Ratain M.J., Eisen T., StadlerW.M. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505—12.18. Escudier B., Szczylik C., Eisen T. et al. Randomized phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 2005;3:226.Escudier B., Szczylik C., Eisen T. et al. Randomized phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 2005;3:226.19. Eisen T., Bukowski R.M., Staehler M. et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. J Clin Oncol 2006;24 (Suppl):4524:abstr 4524.Eisen T., Bukowski R.M., Staehler M. et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. J Clin Oncol 2006;24 (Suppl):4524:abstr 4524.20. Bukowski R.M., Eisen T., Szczylik C. et al. Escudier Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol 2007;25(18S):240:abstr 5023.Bukowski R.M., Eisen T., Szczylik C. et al. Escudier Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol 2007;25(18S):240:abstr 5023.21. Szczylik C., Demkow T., Staehler M. et al. Escudier Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol 2007;25(18S):241:abstr 5025.Szczylik C., Demkow T., Staehler M. et al. Escudier Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol 2007;25(18S):241:abstr 5025.22. Knox J.J., Figlin R.A., Stadler W.M. et al., on behalf of the ARCCS Investigators The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oncol 2007;25(18S):237:abstr 5011.Knox J.J., Figlin R.A., Stadler W.M. et al., on behalf of the ARCCS Investigators The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oncol 2007;25(18S):237:abstr 5011.23. Amato R.J., Harris P., Dalton M. et al. Phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 2007;25(18S):241:abstr 5026.Amato R.J., Harris P., Dalton M. et al. Phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 2007;25(18S):241:abstr 5026.24. Dham A., Dudek A.Z. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol 2007;25(18S):261:abstr 5106.Dham A., Dudek A.Z. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol 2007;25(18S):261:abstr 5106.25. Gollob J., Richmond T., Jones J. et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as firstor second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). J Clin Oncol 2006;24(Suppl):4538:abstr 4538.Gollob J., Richmond T., Jones J. et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as firstor second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). J Clin Oncol 2006;24(Suppl):4538:abstr 4538.26. Ryan C.W., Goldman B.H., Lara P.N. et al. Sorafenib plus interferona2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. J Clin Oncol 2006;24(Suppl):4525:abstr 4525.Ryan C.W., Goldman B.H., Lara P.N. et al. Sorafenib plus interferona2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. J Clin Oncol 2006;24(Suppl):4525:abstr 4525.27. Bracarda S., Porta C., Boni C. et al., GOIRC Study Group. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN) in metastatic renal cell carcinoma (RAP-SODY): GOIRC Study 0681. J Clin Oncol 2007;25(18S):259:abstr 5100.Bracarda S., Porta C., Boni C. et al., GOIRC Study Group. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN) in metastatic renal cell carcinoma (RAP-SODY): GOIRC Study 0681. J Clin Oncol 2007;25(18S):259:abstr 5100.